Search research articles
Contact Us
Filters
Showing results (101-110 of 140) with videos related to
Page
of 14
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)
|
December 31, 2010
Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway
Po-Lin Kuo, Jen-Yu Hung, Shau-Ku Huang, et al.
BMC Cancer
|
May 4, 2021
Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
Yi-Chieh Chen, Ming-Ju Tsai, Mei-Hsuan Lee, et al.
American Journal of Cancer Research
|
November 18, 2024
Comprehensive analysis of the oncogenic potential of eukaryotic initiation factor 3M via SAAL1 interaction in lung adenocarcinoma
Hung-Hsing Chiang, Kuan-Li Wu, Hung-Pei Tsai, et al.
Oncology Reports
|
July 28, 2021
Amine oxidase, copper containing 3 exerts anti‑mesenchymal transformation and enhances CD4<sup>+</sup> T‑cell recruitment to prolong survival in lung cancer
Chao-Yuan Chang, Kuan-Li Wu, Yung-Yun Chang, et al.
Journal of Personalized Medicine
|
June 24, 2022
The Therapeutic Potential of ADAMTS8 in Lung Adenocarcinoma without Targetable Therapy
Hsiao-Chen Lee, Chao-Yuan Chang, Kuan-Li Wu, et al.
Oncology Reports
|
October 4, 2006
Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer
Inn-Wen Chong, Mei-Yin Chang, Huang-Chou Chang, et al.
American Journal of Cancer Research
|
March 8, 2024
Downregulated antisense lncRNA <i>ENTPD3-AS1</i> contributes to the development of lung adenocarcinoma
Hung-Hsing Chiang, Chai-Tung Ong, Chao-Yuan Chang, et al.
Anticancer Research
|
January 30, 2026
First-Line Afatinib 30 mg <i>Versus</i> 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in Taiwan
Hui-Yang Hung, Tai-Huang Lee, Cheng-Hao Chuang, et al.
Plos One
|
May 16, 2024
Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer
Gee-Chen Chang, Jin-Yuan Shih, Chong-Jen Yu, et al.
Journal of Clinical Medicine
|
June 24, 2022
Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis
Tai-Huang Lee, Hsiao-Ling Chen, Hsiu-Mei Chang, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 140) with videos related to
Sort By:
Page
of 14
Journal of Immunology (Baltimore, Md. : 1950)
|
December 31, 2010
Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway
Po-Lin Kuo, Jen-Yu Hung, Shau-Ku Huang, et al.
BMC Cancer
|
May 4, 2021
Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
Yi-Chieh Chen, Ming-Ju Tsai, Mei-Hsuan Lee, et al.
American Journal of Cancer Research
|
November 18, 2024
Comprehensive analysis of the oncogenic potential of eukaryotic initiation factor 3M via SAAL1 interaction in lung adenocarcinoma
Hung-Hsing Chiang, Kuan-Li Wu, Hung-Pei Tsai, et al.
Oncology Reports
|
July 28, 2021
Amine oxidase, copper containing 3 exerts anti‑mesenchymal transformation and enhances CD4<sup>+</sup> T‑cell recruitment to prolong survival in lung cancer
Chao-Yuan Chang, Kuan-Li Wu, Yung-Yun Chang, et al.
Journal of Personalized Medicine
|
June 24, 2022
The Therapeutic Potential of ADAMTS8 in Lung Adenocarcinoma without Targetable Therapy
Hsiao-Chen Lee, Chao-Yuan Chang, Kuan-Li Wu, et al.
Oncology Reports
|
October 4, 2006
Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer
Inn-Wen Chong, Mei-Yin Chang, Huang-Chou Chang, et al.
American Journal of Cancer Research
|
March 8, 2024
Downregulated antisense lncRNA <i>ENTPD3-AS1</i> contributes to the development of lung adenocarcinoma
Hung-Hsing Chiang, Chai-Tung Ong, Chao-Yuan Chang, et al.
Anticancer Research
|
January 30, 2026
First-Line Afatinib 30 mg <i>Versus</i> 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in Taiwan
Hui-Yang Hung, Tai-Huang Lee, Cheng-Hao Chuang, et al.
Plos One
|
May 16, 2024
Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer
Gee-Chen Chang, Jin-Yuan Shih, Chong-Jen Yu, et al.
Journal of Clinical Medicine
|
June 24, 2022
Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis
Tai-Huang Lee, Hsiao-Ling Chen, Hsiu-Mei Chang, et al.
Page
of 14